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Abstract 
Ovarian cancer is the most lethal of all gynecological malignacies and the 
identification of novel prognostic and therapeutic targets for ovarian cancer is crucial. 
It is believed that only a small subset of cancer cells are endowed with stem cell 
properties, which are responsible for tumor growth, metastatic progression and 
recurrence. NANOG is one of the key transcription factors essential for the 
maintaining self-renewal and pluripotency in stem cells. This study investigated the 
role of NANOG in ovarian carcinogenesis and showed overexpression of NANOG 
mRNA and protein in the nucleus of ovarian cancers compared with benign ovarian 
lesions. Increased nuclear NANOG expression was significantly associated with high 
grade cancers, serous histological subtypes, reduced chemosensitivity, and poor 
overall and disease-free survival. Further analysis showed NANOG is an independent 
prognostic factor for overall and disease-free survival. Moreover, NANOG was highly 
expressed in ovarian cancer cell lines with metastasis-associated property and in 
clinical samples of metastatic foci. Stable knockdown of NANOG impeded ovarian 
cancer cell proliferation, migration and invasion, which was accompanied by an 
increase in mRNA expression of E-cadherin, caveolin-1, FOXO1, FOXO3a, FOXJ1 
and FOXB1. Conversely, ectopic NANOG overexpression enhanced ovarian cancer 
cell migration and invasion along with decreased E-cadherin, caveolin-1, FOXO1, 
FOXO3a, FOXJ1 and FOXB1 mRNA expression. Importantly, we found Nanog-
mediated cell migration and invasion involved its regulation of E-cadherin and FOXJ1. 
This is the first report revealing the association between NANOG expression and 
clinical outcome of patients with ovarian cancers, suggesting NANOG to be a 
potential prognostic marker and therapeutic molecular target in ovarian cancer.  
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Introduction 
Ovarian cancer is a common gynecological cancer world-wide and contributes to high 
mortality, despite advances in treatment modalities.1 The poor prognosis is due to a 
lack of symptoms at early stages until widespread metastasis develops and the high 
rates of chemoresistance found in patients with advanced diseases.2 In consequence, it 
is vital to identify novel prognostic markers and therapeutic targets for ovarian cancer. 
 
NANOG is one of the core transcription factors expressed in pluripotent embryonic 
stem (ES) cells but not in somatic organs.3, 4 NANOG plays essential roles in 
maintaining self-renewal and the undifferentiated state of pluripotent stem cells 
during early embryonic development. Besides controlling such “stemness” properties, 
the role of NANOG in tumorigenesis has attracted attention.5 
 
Increasing evidence has suggested that most tumors are heterogeneous. Of which, a 
small subset of cells, known as cancer stem cells, arise from mutated adult 
stem/progenitor cells possessing stem-like properties, which are responsible for tumor 
growth, metastasis, chemoresistance, and thus cancer recurrence. Only by targeting 
these population of cells which exhibit a number of important phenotypic, biological 
and functional characteristics associated with normal stem cells can one ultimately 
cure the disease.6, 7 Therefore, cancer stem cell markers, which are good therapeutic 
targets in common cancers, are being vigorously investigated.8, 9 
 
 
Recent studies have identified and characterized a self-renewing subpopulation of 
cancer-initiating cells in ovarian cancers endowed with stem-like properties and 
induced NANOG expression.9-11 In addition, NANOG expression has also been found 
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in an ovarian cancer cell line and is involved in multidrug resistance.12 In this study, 
we investigated the prognostic significance of NANOG in ovarian cancer and 
assessed for the first time the functional roles and putative downstream targets of 
NANOG in ovarian cancer. Our results suggest that NANOG may be one of cancer stem 
cell markers that play a central role in the progression of ovarian cancers. As such, NANOG 
could also be an important prognostic marker for identifying patients who respond better to 
current treatment regimes as well as a therapeutic target for ovarian cancer treatment. 
 
Results 
NANOG is overexpressed in the nucleus of ovarian cancers and associated with 
tumor aggressiveness, metastasis and chemosensitivity. By immunohistochemistry, 
no nuclear NANOG immunostaining was detected in benign cystadenomas, whereas 
weak to moderate expression was found in borderline tumors and ovarian cancers 
respectively (Figure 1a). In terms of the percentage of positive cells, around 2 to 20% 
cancer cells were stained in borderline tumors and ovarian cancers respectively (Table 
1). The differential nuclear NANOG immunoreactivity (i.e. histoscore as mentioned 
in Methods) among the three diagnostic categories, including benign, borderline and 
carcinomas, were statistically significant (p=0.031) (Table 1). Moreover, statistically 
higher nuclear NANOG immunoreactivity was found in metastatic foci than their 
corresponding primary carcinomas (p=0.005) (Figure 1a and Table 1).  High nuclear 
NANOG immunoreactivity was significantly associated with poor histological grade, 
serous histological subtypes and chemosensitivity (all p<0.05; Table 1). Similar trend 
was also obtained when percentage, but not intensity, of NANOG stained cells was 
used for analyses (Table 1). Significantly higher NANOG mRNA levels were also 
found in ovarian cancers than in benign cystadenomas as detected by qPCR (p=0.046) 
(Figure. 1b i). The result also revealed that the mRNA expression of SOX-2 and 
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OCT-4, two other core stem cell transcription factors,13 was also overexpressed in 
ovarian cancers (Figure 1b ii and iii). 
 
NANOG overexpression is associated with poor prognosis of ovarian cancer 
patients. Univariate analysis revealed that NANOG was significantly associated with 
shorter overall (p=0.001) and disease-free (p=0.002) survival (Figure 2). Similar 
trends were also observed when either intensity or percentage of NANOG 
immunoreactive cells was used for analyses (data not shown). By multivariate 
analysis, NANOG, disease stage and chemosensitivity remained significant predictors 
for overall survival, whereas NANOG, disease stage and debulking remained 
significant predictors for disease-free survival (all p<0.05, Supplementary Table 3) 
 
NANOG is overexpressed in ovarian cancer cell lines and localized in the nucleus 
of cancer cells.  By qPCR, NANOG mRNA expression was higher in five (OVCA 
433, OVCAR-3, PA-1, SKOV-3 and SW626) and lower in two (OVCA 420 and 
TOV112D) out of twelve ovarian cancer cell lines compared to the three normal 
HOSE cell lines. In particular, NANOG mRNA expression in SKOV-3 and OVCAR-
3, two cell lines produced from metastatic ovarian cancers, was at least 6- to 8-fold 
higher than the normal HOSE cell lines (Figure 3a). Moreover, we found that 
NANOG mRNA expression was about 9-fold higher in 2008-C13 (cisplatin-resistance) 
than in the 2008 (cisplatin-sensitive) cell lines (Figure 3b). Subcellular expression of 
NANOG in nuclear and cytoplasmic fractions of OVCAR-3 was also determined by 
immunoblotting. Concurring with the immunohistochemical findings, NANOG 
protein expression was predominately found in the nuclear fraction, with no 
detectable expression in the cytoplasmic fraction (Figure 3c).  
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Knockdown of NANOG impedes ovarian cancer cell proliferation, migration and 
invasion, down-regulates SOX-2 and up-regulates E-cadherin and caveolin-1 
mRNA expression. Stable knockdown of NANOG in OVCAR-3 was detected at both 
mRNA and protein levels (Figure 4a). We found that stable knockdown of NANOG 
significantly retarded cell proliferation after 12 d (Figure 4b). Moreover, Transwell 
migration and invasion assays revealed significantly reduced migration and invasion 
(p<0.05) in shNANOG OVCAR-3 compared with that in control (Figure 4c). In 
addition, specific transient (siNanog#1 and #2; Supplementary Figure 1a) knockdown 
of NANOG in SKOV-3 significantly reduced migration and invasion (Supplementary 
Figure 1b). Next, we investigated the effect of NANOG depletion on mRNA 
expression of SOX-2 and OCT-4, two other core stem cell transcription factors,13 and 
E-cadherin, caveolin-1 and integrin-beta(β) 1, all are possible downstream targets for 
cell migration and invasion.14, 15 In fact, previous study documented that NANOG can 
bind to specific promoter elements of SOX-2, OCT-4, caveolin-1 and integrin-β1 in 
embryonic stem cells.13 We found that depletion of NANOG expression in OVCAR-3 
cells significantly decreased SOX-2, and up-regulated E-cadherin and caveolin-1, but 
have no virtual effect on OCT-4 and integrin-β1 mRNA expression (Figure 4d). 
Moreover, up-regulation of E-cadherin and caveolin-1 in protein level was also 
demonstrated in NANOG depleted OVCAR-3 cells (Figure 4d, inset). Transient 
knockdown of NANOG in SKOV-3 also significantly decreased SOX-2, and up-
regulated E-cadherin, but have no virtual effect on OCT-4, caveolin-1 and integrin-β1 
mRNA expression (Supplementary Figure 1c). 
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Knockdown of NANOG enhances FOXO1, FOXO3a, FOXJ1 and FOXB1 
mRNA expression. Forkhead box (FOX) proteins are a large family of transcriptional 
regulators, which control a variety of biological processes leading to alteration of cell 
fate, thus the development and progression of cancer.16 Since four FOX proteins, 
including FOXO1, FOXO3a, FOXJ1 and FOXB1, are likely targets of NANOG in 
embryonic stem cells,13 we investigated their mRNA expression in NANOG depleted 
OVCAR-3 and SKOV-3 cells. qPCR analysis revealed that stable knockdown of 
NANOG in OVCAR-3 up-regulated all four FOX proteins from around 2 to 13 folds 
(Figure 5a) and transient knockdown of NANOG in SKOV-3 up-regulated FOXO1, 
FOXO3a and FOXJ1, but not FOXB1 (Supplementary Figure 1c). Among them, 
increasing number of studies documented that FOXO are cellular targets of antitumor 
drugs in malignancies, including ovarian cancer.16, 17 As a consequence, we further 
explored if NANOG can regulate FOXO1 and FOXO3a transcription activities. Our 
results showed that both FOXO1 (Figure 5b, left panel) and FOXO3a (Figure 5b, right 
panel) promoter activities were evaluated in NANOG depleted OVCAR-3 cells.  
  
Overexpression of NANOG promotes cell migration and invasion in association 
with induced SOX-2 and attenuated E-cadherin, caveolin-1, FOXO1, FOXO3a 
FOXJ1 and FOXB1 mRNA expression. To further study the effect and downstream 
targets of NANOG in ovarian cancer cell migration and invasion, ectopic 
overexpression of NANOG in OVCA420 was performed (Figure 6a). Significantly 
increased cell migration and invasion (Figure 6b) as well as up-regulation of SOX-2 
and down-regulation of E-cadherin, caveolin-1, FOXO1, FOXO3a, FOXJ1 and 
FOXB1 mRNA expression (Figure 6c) was demonstrated in NANOG-overexpressing 
OVCA420 cells when compared with the pcDNA3.1 control.  
 9
 
Nanog-mediated cell migration and invasion involves E-cadherin and FOXJ1. To 
test if Nanog-mediated cell migration and invasion is dependent on E-cadherin and 
FOXJ1, NANOG depleted OVCAR-3 cells were treated with specific siRNAs of E-
cadherin and FOXJ1. E-cadherin and FOXJ1 mRNA expression was reduced by 80% 
in siRNA-treated cells when compared with control cells (Supplementary Figure 2). 
Treatment with siRNAs against E-cadherin and FOXJ1 also increased basal cell 
migration and invasion, and rescued NANOG-reduced migration and invasion (Figure 
5c). Similar results were obtained when another set of siRNAs were used (data not 
shown). In addition, OVCA420 cells were transiently transfected with NANOG and 
E-cadherin (Figure 6d). Ectopically expressed E-cadherin decreased cell migration 
and invasion and inhibited NANOG-mediated migration and invasion (Figure 6e). 
 
Discussion 
In this study, we showed significantly higher NANOG immunoreactivity in ovarian 
cancer samples when compared with borderline tumors and benign 
cystadenomas/inclusion cysts. Expression of NANOG mRNA and that of two other 
core stem cell transcription factors, SOX-2 and OCT-4, was also detected in ovarian 
cancer. In vitro, we found that SOX-2 can be regulated by NANOG in ovarian cancer 
cells. Interestingly, in borderline tumor and ovarian cancer clinical samples, only 
around 2 to 20% cancer cells were NANOG-positive, respectively. Cancer stem cells 
are a small population of cells found in a given malignant tissue.8 The present finding 
showing a small portion of NANOG positive tumor cells in ovarian tumors concur 
with this property, suggesting NANOG is not only involved in ovarian cancer 
progression, but also may be one of cancer stem cell makers. In agreement, cancer 
 10
stem-like cells isolated from ascites derived from ovarian cancer patients,18 prostate 
tumors,19 oral squamous cell carcinoma20 and osteosarcoma21 also showed elevated 
NANOG expression.  
 
Significantly higher NANOG immunoreactivity was detected in poorly differentiated 
ovarian cancers, serous histological subtypes and in metastatic foci when compared 
with their corresponding primary ovarian cancers. In vitro, NANOG mRNA 
expression was also particularly high in SKOV3 and OVCAR-3, which are derived 
from the malignant ascites of patients diagnosed with serous adenocarcinoma.22 These 
serous-type tumors account for ~70% of ovarian cancers,23 and are often associated 
with ascites formation and intraperitoneal metastases.24 These findings suggest 
NANOG to be involved in ovarian cancer de-differentiation and metastasis which are 
two important cancer stem cell properties.8, 19, 20 We also found lower NANOG 
mRNA expression in endometrioid tumor-derived TOV112D cell line25 compared to 
the three normal HOSE cell lines which consistent with the relatively lower NANOG 
immunoreactivity in endometrioid ovarian cancers. More importantly, we 
demonstrated a significant correlation between high NANOG immunoreactivity and 
shorter overall and disease free survival, suggesting NANOG to be an important 
prognostic marker in ovarian cancer. NANOG is an independent prognostic factor for 
overall survival.  
 
If high NANOG expression can be further confirmed to indicate poor prognosis, as 
suggested in this report, it may serve as a biomarker to assist in triage of patients with 
early stage ovarian cancers and decision for adjunct therapy. Ovarian cancer patients 
diagnosed with stage I (confined to ovary) disease do not need adjuvant chemotherapy 
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unless they are associated with poor prognostic parameters such as high grade cancers 
(high grade serous or clear cell types) or capsular involvement. Even under such 
situations, single agent therapy by carboplatin can be administered instead of 
combination with paclitaxel as in patients with higher staged disease. Moreover, 
maintenance molecular targeted therapy such as bevacizumab is also being 
investigated for patients with poor prognosis. High NANOG expression may serve as 
a marker for indicating combination instead of single agent chemotherapy in stage I 
patients as well as to select high risk patients for administering adjunct targeted 
therapy to improve their clinical outcome. Larger scale studies are needed to confirm 
such application. 
 
Ovarian cancer-initiating cells isolated from primary tumors with overexpressed 
NANOG and other stem cell markers was shown to enhance chemoresistance to the 
ovarian cancer chemotherapeutics cisplatin or paclitaxel.10 Cancer stem-like cells 
isolated from osteosarcoma also showed evaluated NANOG expression along with 
chemoresistance.21 Moreover, HA treatment of ovarian and breast cancer cells 
induced Stat-3 bound to NANOG and favored Stat-3-specific transcriptional 
activation leading to MDR1 gene expression and multidrug resistance.12 Thus, 
increasing evidence showed that conventional anticancer therapies are mostly unable 
to remove cancer stem cell clones and instead help cancer stem cell expand and/or 
select for resistant cancer stem cell clones, leading to cancer patient relapse.8 In this 
study, significantly higher NANOG immunoreactivity in chemoresistant ovarian 
cancer samples and cell lines was detected. We also found up-regulation of FOXO1 
and FOXO3a transcription activities and mRNA levels after stable knockdown of 
NANOG in ovarian cancers as well as down-regulation of FOXO1 and FOXO3a 
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mRNA expression in NANOG-overexpressing cells, suggesting NANOG to be a 
negative regulator of FOXO1 and FOXO3a. Given that FOXO transcription factors 
are cellular targets of anticancer drugs in multiple cancers16, 17 and low FOXO3a 
expression is associated with poor prognosis in ovarian cancer patients,26 it is possible 
that NANOG affect chemosensitivity through transcription regulation of FOXO1 and 
FOXO3a which will be studied in near future. 
 
Functionally, we found knockdown of NANOG reduced ovarian cancer cell 
proliferation, migration and invasion along with up-regulated E-cadherin and 
caveolin-1, whilst ectopic overexpression of NANOG led to increased cell migration 
and invasion along with down-regulated E-cadherin. We have previously reported 
positive effect of NANOG on choriocarcinoma cell migration and invasion.27 In 
ovarian cancer cells, simultaneous expression of caveolin-1 and E-cadherin found to 
stabilize adherens junctions through inhibition of src-related kinases.28 In contrast, 
depletion of E-cadherin promoted ovarian cancer metastasis through induced α5-
integrin expression.15 In vivo, NANOG expression pattern is opposite to E-cadherin 
expression in ovarian cancers where reduced E-cadherin expression was found at 
metastatic sites when compared with their primary ovarian tumors.29 Moreover, a 
significantly shorter survival was found in ovarian cancer patients with negative E-
cadherin expression.30 Importantly, our rescue experiments demonstrated Nanog-
mediated cell migration and invasion in E-cadherin dependent manner. 
 
FOXJ1 has been found to suppress inflammation through repression of NF-κB.31 
Besides being as an important mediator of immune response, NF-κB is also involved 
in regulating tumor growth, apoptosis and metastasis, thus tumorigenesis. FOXJ1 was 
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hypermethylated in breast tumor cell lines and clinical samples, suggesting being a 
putative tumor suppressor gene.32 While the mechanisms through which FOXJ1 
suppress tumor growth remains unknown, our findings implicate FOXJ1 as one of the 
downstream mediators of NANOG in regulating cell migration and invasion and 
suggest that FOXJ1 suppress tumor progression though regulation on cellular 
processes in metastasis.  
 
In conclusion, our in vivo and in vitro findings demonstrated NANOG, an important 
stem cell related transcription factor, to be involved in ovarian tumorigenesis probably 
through regulating chemosensitivity, cell proliferation, migration and invasion. 
NANOG is a negative regulator of E-cadherin and FOXJ1 in mediating ovarian 
cancer cell migration and invasion. Importantly, NANOG is a potential prognostic 
marker and molecular therapeutic target in ovarian cancer.  
 
Materials and Methods 
Clinical samples. Archived formalin-fixed paraffin-embedded tissue blocks in 
ovarian cancer, with the corresponding clinical follow-up data were retrieved from 
Department of Pathology, the University of Hong Kong, Queen Mary Hospital 
including six benign cystadenomas (age range 20-35 years, mean age 34.8 years), 
seven borderline tumors (age range 20-46 years, mean age 28.9 years), 97 carcinomas 
(age range 32-83 years, mean age 50.5 years) with different histological subtypes and 
43 corresponding metastatic foci of ovarian cancers for studying NANOG protein 
expression. Among patients with ovarian cancers, 80 received chemotherapy 
including platinum/paclitaxel after surgery, and the median follow-up period was 63 
months (range, 4-209 months). Twenty-eight randomly selected ovarian tumors 
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clinical samples with available frozen blocks including three benign cystadenomas 
and twenty-five ovarian cancers were also retrieved for studying mRNA expression of 
NANOG, SOX-2 and OCT-4. The use of these samples was approved by the 
Institutional Ethical Review Board. The diagnosis of each sample was assessed by 
pathologists and ensured to have more than 70% tumor cells. 
 
Cell lines, subcellular protein extraction and treatment. Three immortalized human 
normal ovarian epithelial cell lines, HOSE 6-3, HOSE 11-12 and HOSE 17-1, and 
fourteen ovarian cancer cell lines, DOV13, ES2, OC316, OVCA 420, OVCA 433, 
OVCAR-3, PA-1, SKOV-3, SW626, TOV21G, TOV112D, 2008 and 2008-C13 were 
cultured as previously described.33, 34 HOSE 6-3, HOSE 11-12, HOSE 17-1, OVCA 
420 and OVCA 433 were provided by Prof. S.W. Tsao (Department of Anatomy, the 
University of Hong Kong). OVCAR-3, SKOV-3 and SW626 were from ATCC 
(Manassas, VA). 2008 and 2008-C13 cells were established by Dr. S. B. Howell 
(University of California at San Diego, La Jolla, CA) and provided by Dr. Z. H. Siddik 
(M. D. Anderson Cancer Center).35, 36 Cytoplasmic and nuclear extracts from 
OVCAR-3 cells were isolated using the NE-PER® Nuclear and Cytoplasmic 
Extraction Reagents (Pierce Biotechnology, Rockford, IL).33, 34 
 
Stable knockdown of NANOG in OVCAR-3. Small hairpin RNA (shRNA) 
constructs targeting human NANOG (pRS-shNANOG with puromycin resistant gene; 
Origen, Rockville, MD) were stably transfected into OVCAR-3 cells using 
Lipofectamine 2000 (Invitrogen, San Diego, CA), while pRS empty vector (pRS-
shControl; Origen) transfected cells were used as control.27, 33 Stable clones were 
selected with puromycin (1.875µg/ml).  
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Transient knockdown of NANOG in SKOV-3 and E-cadherin and FOXJ1 in 
OVCAR-3. Cells were transfected with two siRNAs of NANOG, E-cadherin and 
FOXJ1 (Ambion, TX, USA) using SilentFectTM (Bio-Rad Laboratories, Hercules, CA) 
per manufacturer’s instructions for 48 hours before cell counting and cell plating. 
Silencer® Select Negative Control siRNA (Ambion) was used as control. 
 
Ectopic overexpression of NANOG and E-cadherin in OVCA420. The pcDNA3.1-
NANOG and pcDNA3.1-E-cadherin plasmids were obtained from Addgene 
(www.addgene.org). Cells were transfected with NANOG and E-cadherin or the 
control vector using PolyJetTM DNA In Vitro Tranfection Reagent (SignaGen 
Laboratories, Rockville, MD) for 48 hours before cell counting and cell plating. 
 
Immunohistochemistry. Immunohistochemical staining was performed as 
described.27, 34 Antibody against NANOG (ab21603; Abcam, Cambridge, MA) at a 
dilution of 1:50 was applied to deparaffinized sections and tested using EnVision+ 
Dual Link System (K4061; Dako, Carpinteria, CA). Antigen recovery was performed 
by heating in a pressure cooker using 10mM EDTA (pH 8.0). Elimination or 
replacement of the primary antibody with preimmune IgG serum was acted as a 
negative control. Both the intensity and percentage of stained epithelial cells were 
evaluated semiquantitatively. Staining intensity was scored as 0 (negative), 1 (faint), 2 
(moderate), and 3 (strong). The percentage of positive cells was rated as 0 (<5%), 1 
(5%-25%), 2 (26%-50%), 3 (51%-75%) and 4 (>75%). Only nuclear staining was 
considered as positive. The immunoreactivity was assessed by multiplying the staining 
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intensity by the percentage of stained cells to give a composite “histoscore”. High and 
low expression levels of NANOG were defined by the “histoscores” cut off at mean.  
 
Real-time PCR (qPCR). Total RNA extracted from cancer cell lines was reverse 
transcribed by SuperScript Reverse Transcriptase (Invitrogen). qPCR was done using 
ABI Prism 7700 sequence detection system (Applied Biosystems, Foster City, CA) as 
described.27, 33 Primer sequences were listed in Supplementary Table 1. 
 
Immunoblotting. 20 μg protein lysate was resolved by SDS-PAGE, eletroblotted to 
polyvinylidene difluoride membrane, and hybridized with corresponding antibodies.27, 
34 Antibodies used in this study were listed in Supplementary Table 2. 
 
Cell proliferation was determined by cell count method. Cells (3 x 104) were 
seeded in T150 culture flasks and maintained in growth medium.34 Cell number was 
counted using trypan blue dye exclusion with hematocytometer at day 12.  
 
In vitro migration and invasion assays. In vitro migration and invasion assays were 
done as previously described.27, 34 OVCAR-3 cells (1.25 x 105) were plated on the 
upper side of a Transwell chamber. Cells migrated through an 8-µm pore size 
membrane (migration assay) and Matrigel–coated membrane (invasion assay were 
assessed respectively. After 24 hours (migration assay) or 48 hours (invasion assay), 
cells on the upper compartment of the membrane were removed and the migrated or 
invaded cells at the lower surface of the membrane were fixed, stained, and counted.  
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Luciferase reporter assay. Control and shNANOG OVCAR-3 cells were transiently 
transfected with pGL3-Basic empty vector (negative control), pGL3-Basic-FOXO1A-
Luc (bp -1609/+230) or pGL3-Basic-FOXO3-Luc (bp 1480/-25) reporter plasmids. 
pRL-SV40-Luc was used as internal control. Cells were lysed 48h post-transfection. 
Luciferase activity was analyzed using the Dual-Luciferase Reporter Assay System 
(Promega, Madison, WI) as previously described.37 Transfection efficiency was 
normalized by Renilla luciferase activities.  
 
Statistical Analysis. Statistical analysis was performed using SPSS 15.0 for Windows 
(SPSS Inc., Chicago, IL). Mann-Whitney test and Kruskal–Wallis rank test were used 
for comparison of data between two groups and among multiple groups respectively. 
Kaplan–Meier analysis and log-rank test were used for survival analysis. Multivariate 
survival analysis was done using Cox regression analysis. P values < 0.05 were 
considered as statistically significant.  
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Figure legends 
 
Figure 1. Overexpressed NANOG in ovarian cancer associated with tumor 
aggressiveness, metastasis and chemosensitivity. (a) Immunohistochemical staining of 
NANOG in serous benign cystadenomas (i), serous borderline tumors (ii), serous 
carcinomas (iii) with corresponding metastatic foci (iv), mucinous benign 
cystadenomas (v), mucinous borderline tumors (vi), mucinous carcinomas (vii), 
endometrial carcinomas (viii), clear cell carcinomas (ix), chemosensitive (x) and 
chemoresistant (xi) ovarian carcinomas. Insets highlight regions with higher 
magnification. (b) qPCR analysis of (i) NANOG, (ii) SOX-2 and (iii) OCT-4  mRNA 
in ovarian tumors as shown in scatter plots with a line at mean. The fold change of the 
target gene expression was calculated with respect to the mean expression of the 
target gene in benign cystadenomas.  
 
Figure 2. Increase in NANOG expression was significantly associated with poor 
overall (a) and disease-free (b) survival in the univariate analysis (cut off at mean). 
 
Figure 3. Overexpressed NANOG in ovarian cancer cell lines and localization of 
NANOG in the nucleus of ovarian cancer cells. (a) NANOG mRNA expression in 
HOSE cell lines and ovarian cancer cell lines as determined by qPCR (Bars, 
means±SD of three experiments; *, p<0.05; **, p<0.005 compared with HOSE 6-3, 
Mann-Whitney test). (b) NANOG mRNA expression in chemosensitive (2008) and 
chemoresistant (2008-C13) cell lines as determined by qPCR (**, p<0.005 compared 
with 2008). (c) NANOG in subcellular protein fractions of OVCAR-3 (T: total cell 
lysate, C: cytoplasmic fraction, N: nuclear fraction).  
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Figure 4. NANOG depletion reduced OVCAR-3 cell migration and invasion, down-
regulated SOX-2, and up-regulated E-cadherin and caveolin-1. (a) Stable knockdown 
of NANOG mRNA and protein in OVCAR-3 as detected by qPCR and 
immunoblotting (inset) respectively. (b) Cell proliferation rate of OVCAR-3 in 
control and shNANOG after 14 days displayed as fold change compared to control; 
n=3; **, p<0.005. (c) In vitro migration and invasion assays using Transwell 
membrane without or with Matrigel coating respectively. Upper panel: representative 
images of migrating or invading cells. Lower panel: Cell migration or invasion 
presented as percentage of control; n=3; **, p<0.005, Mann-Whitney test. (d) mRNA 
expression of SOX-2, OCT-4, E-cadherin, caveolin-1 and integrin-β1 in control and 
shNANOG OVCAR-3 as determined by qPCR analysis. Bars, means±SD of three 
experiments; *, p<0.05; **, p<0.005, Mann-Whitney test. Protein expression of E-
cadherin, caveolin-1 in control and shNANOG OVCAR-3 as determined by 
immunoblotting (inset). 
 
Figure 5. NANOG depletion up-regulated FOXO1, FOXO3a, FOXJ1, FOXD3 and 
FOXB1 and enhanced FOXO1 and FOXO3a promoter activities. Nanog-mediated cell 
migration and invasion involved E-cadherin and FOXJ1. (a) mRNA expression of 
FOXO1, FOXO3a, FOXJ1 and FOXB1 in control and shNANOG OVCAR-3 as 
determined by qPCR analysis. Bars, means±SD of three experiments; *, p<0.05; **, 
p< 0.005, Mann-Whitney test. (b) FOXO1 (left panel) and FOXO3a (right panel) 
promoter activities in control and shNANOG OVCAR-3 cells as determined by dual 
luciferase assays. Bars, means±SD of three experiments; *, p<0.05, Mann-Whitney 
test. (c) In vitro migration (left panel) and invasion (right panel) assays in control and 
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shNANOG OVCAR-3 cells combined with siRNAs of E-cadherin and FOXJ1. Cell 
migration or invasion presented as percentage of control; n=3; *, p<0.05, **, p<0.005. 
 
Figure 6. NANOG overexpression enhanced OVCA420 cell migration and invasion, 
up-regulated SOX-2, and down-regulated E-cadherin, caveolin-1, FOXO1, FOXO3a, 
FOXJ1, FOXD3 and FOXB1.  Nanog-mediated cell migration and invasion involved 
E-cadherin. (a) Ectopic overexpression of NANOG mRNA in OVCA420 as detected 
by qPCR. (b) In vitro migration and invasion assays using Transwell membrane 
without or with Matrigel coating respectively. Cell migration or invasion presented as 
percentage of control; n=3; **, p<0.005, Mann-Whitney test. (c) mRNA expression of 
SOX-2, OCT-4, E-cadherin, caveolin-1, integrin-β1, FOXO1, FOXO3a, FOXJ1 and 
FOXB1 in control and NANOG-overexpressing OVCA420 as determined by qPCR 
analysis. Bars, means±SD of three experiments; *, p<0.05; **, p<0.005, Mann-
Whitney test. (d) Ectopic overexpression of NANOG (left panel) and E-cadherin 
(right panel) mRNA in OVCA420 as detected by qPCR. (e) In vitro migration (left 
panel) and invasion (right panel) assays in control and NANOG-overexpressing 
OVCA420 cells combined with ectopic overexpression of E-cadherin. Cell migration 
or invasion presented as percentage of control; n=3; *, p<0.05, **, p<0.005. 
 
Supplementary Figure 1. Transient knockdown of NANOG impeded SKOV-3 cell 
migration and invasion, down-regulated SOX-2, and up-regulated E-cadherin, 
FOXO1, FOXO3a and FOXJ1. (a) Transient knockdown of NANOG mRNA in 
SKOV-3 as detected by qPCR. (b) In vitro migration and invasion assays using 
Transwell membrane without or with Matrigel coating respectively. Cell migration or 
invasion presented as percentage of control; n=3; **, p<0.005, Mann-Whitney test. (c) 
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mRNA expression of SOX-2, OCT-4, E-cadherin, caveolin-1, integrin-β1, FOXO1, 
FOXO3a, FOXJ1 and FOXB1 in control and siNANOG SKOV-3 as determined by 
qPCR analysis. Bars, means±SD of three experiments; *, p<0.05; **, p<0.005, Mann-
Whitney test.  
 
 
Supplementary Figure 2. Transient knockdown of mRNA expression of E-cadherin 
(let panel) and FOXJ1 (right panel) in OVCAR-3 cells detected by qPCR. 
 
Table 1. Correlation of the intensity or percentage of NANOG immunoreactive cells and NANOG 
histoscore with different diagnostic categories and clinicopathological parameters in ovarian cancer.  
Characteristics Case 
(n) 
NANOG (intensity) NANOG (percentage) NANOG (histoscore) 
  Mean ± SD p-value Mean ± SD p-value Mean ± SD p-value 
Diagnostic categories        
Benign 6 0±0  0±0  0±0  
Borderline 7 0.29±0.49  2.1±3.9  0.29±0.49  
Carcinomas 97 1.02±1.16 0.018* 21.7±30.7 0.019* 1.07±1.68 0.031* 
Carcinomas‡ 24 0.62±0.98  13.9±25.4  0.59±0.93  
Metastatic foci‡ 43 1.42±1.24 0.004† 28.1±32.4 0.015† 2.23±2.86 0.005† 
Stage (FIGO)        
I 35 1.08±1.08  20.8±29.5  0.97±1.41  
II 14 0.64±1.08  5.4±10.7  0.42±0.97  
III 30 1.07±1.26  23.2±30.4  1.50±2.27  
IV 13 1.23±1.30 0.464* 26.9±33.9 0.207* 1.20±1.39 0.304*
Early (I-II)  49 0.96±1.09  16.5±26.5  0.81±1.31  
Late (III-IV) 43 1.12±1.26 0.659† 24.3±31.1 0.386† 1.41±2.03 0.340† 
Histological grade 
(FIGO) 
       
1 19 0.84±1.21  4.0±7.2  0.24±0.46  
2 42 1.26±1.21  26.0±30.7  1.45±1.83  
3 34 0.76±1.02 0.119* 22.2±33.6 0.043* 1.10±1.82 0.041* 
Low (1)  19 0.84±1.21  4.0±7.2  0.24±0.46  
High (2-3) 76 1.04±1.15 0.372† 24.3±31.8 0.031† 1.29±1.82 0.040† 
Histology        
Serous 37 1.26±1.19  28.4±31.5  1.50±1.81  
Clear Cell 22 0.86±1.13  20.9±33.9  0.96±1.38  
Mucinous 7 1.14±1.46  17.9±25.8  1.56±3.08  
Endometrioid 31 0.84±1.07 0.374* 13.2±24.6 0.171* 0.67±1.28 0.183* 
Serous  37 1.26±1.19  28.4±31.5  1.50±1.81  
Non-serous 60 0.88±1.12 0.089† 16.6±28.2 0.031† 0.88±1.60 0.035† 
Chemosensitivity§         
Sensitive 65 0.91±1.11  16.0±26.9  0.76±1.38  
Resistant 15 1.33±1.23 0.162† 39.3±34.2 0.020† 2.38±2.55 0.019† 
Debulking¶        
Optimal   56 1.11±1.17  20.6 ±29.0  1.09±1.67  
Suboptimal 10 0.60±0.70 0.261† 16.5±30.5 0.550† 0.78±1.77 0.423† 
        
Cycles of chemotherapy        
≤ 6 55 0.86±1.08  17.9±29.0  0.97±1.70  
> 6 12 1.33±1.61 0.508† 23.3±38.5 0.752† 1.53±2.48 0.661† 
*Kruskal–Wallis rank test; †Mann-Whitney test; ‡Randomly selected primary carcinomas with 
matched metastatic foci. §Chemosensitive-patients remained disease free more than 6 months after 
completion of first-line chemotherapy; ¶Optimal debulking referred to minimal residual disease (≤ 1 
cm in maximal diameter).  Those with significant P-values were underlined.  






